188 related articles for article (PubMed ID: 30787429)
1. Impact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma.
Goyal G; Rajkumar SV; Lacy MQ; Gertz MA; Buadi FK; Dispenzieri A; Hwa YL; Fonder AL; Hobbs MA; Hayman SR; Zeldenrust SR; Lust JA; Russell SJ; Leung N; Kapoor P; Go RS; Gonsalves WI; Kourelis TV; Warsame R; Kyle RA; Kumar SK
Leukemia; 2019 May; 33(5):1273-1277. PubMed ID: 30787429
[TBL] [Abstract][Full Text] [Related]
2. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
[TBL] [Abstract][Full Text] [Related]
3. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
[TBL] [Abstract][Full Text] [Related]
5. Does my patient with a serum monoclonal spike have multiple myeloma?
Bianchi G; Ghobrial IM
Hematol Oncol Clin North Am; 2012 Apr; 26(2):383-93, ix. PubMed ID: 22463833
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA
Eur J Haematol Suppl; 1989; 51():70-5. PubMed ID: 2516809
[TBL] [Abstract][Full Text] [Related]
7. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.
Dutoit JC; Vanderkerken MA; Anthonissen J; Dochy F; Verstraete KL
Eur Radiol; 2014 Nov; 24(11):2754-65. PubMed ID: 25106487
[TBL] [Abstract][Full Text] [Related]
9. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.
Pérez-Persona E; Vidriales MB; Mateo G; García-Sanz R; Mateos MV; de Coca AG; Galende J; Martín-Nuñez G; Alonso JM; de Las Heras N; Hernández JM; Martín A; López-Berges C; Orfao A; San Miguel JF
Blood; 2007 Oct; 110(7):2586-92. PubMed ID: 17576818
[TBL] [Abstract][Full Text] [Related]
10. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
Kyle RA; Rajkumar SV
Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
[TBL] [Abstract][Full Text] [Related]
11. Smoldering multiple myeloma current treatment algorithms.
Rajkumar SV; Kumar S; Lonial S; Mateos MV
Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
[TBL] [Abstract][Full Text] [Related]
14. Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study.
Chang SH; Luo S; O'Brian KK; Thomas TS; Colditz GA; Carlsson NP; Carson KR
Lancet Haematol; 2015 Jan; 2(1):e30-6. PubMed ID: 26034780
[TBL] [Abstract][Full Text] [Related]
15. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
Mateos MV; Landgren O
Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
González-Calle V; Mateos MV
Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
[TBL] [Abstract][Full Text] [Related]
17. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis.
Rajkumar SV; Mesa RA; Fonseca R; Schroeder G; Plevak MF; Dispenzieri A; Lacy MQ; Lust JA; Witzig TE; Gertz MA; Kyle RA; Russell SJ; Greipp PR
Clin Cancer Res; 2002 Jul; 8(7):2210-6. PubMed ID: 12114422
[TBL] [Abstract][Full Text] [Related]
18. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.
El-Khoury H; Lee DJ; Alberge JB; Redd R; Cea-Curry CJ; Perry J; Barr H; Murphy C; Sakrikar D; Barnidge D; Bustoros M; Leblebjian H; Cowan A; Davis MI; Amstutz J; Boehner CJ; Lightbody ED; Sklavenitis-Pistofidis R; Perkins MC; Harding S; Mo CC; Kapoor P; Mikhael J; Borrello IM; Fonseca R; Weiss ST; Karlson E; Trippa L; Rebbeck TR; Getz G; Marinac CR; Ghobrial IM
Lancet Haematol; 2022 May; 9(5):e340-e349. PubMed ID: 35344689
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
Schmidt T; Callander N
J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
